Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs) — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs)
Department of Pathology, Ain Shams University, Cairo, Egypt
,
Department of Pathology, Ain Shams University, Cairo, Egypt
,
International Medical Center, Cairo, Egypt
,
Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
,
Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
1 Department of Pathology, Ain Shams University, Cairo, Egypt
2 Department of Pathology, Ain Shams University, Cairo, Egypt
3 International Medical Center, Cairo, Egypt
4 Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
5 Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
6 Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
7 Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Background & objectives: Presence of TILs in breast cancer indicates better therapeutic responses to neoadjuvant chemotherapy (NAC), increased pCR and improved outcome. We aim at evaluation of TILs in breast cancer biopsies in correlation with pathological response after NAC in locally advanced breast cancer Methods. This study was conducted at Ain Shams university hospital and Maadi Military hospital in Egypt. 45 Female patients with locally advanced breast cancer were treated with NAC ; pathological response was assessed. Tumours were categorized into: luminal A, luminal B, Her2 enriched and TNBC. Assessment of TILs (CD4 and CD8 lymphocytes) was based on Immuno-Oncology Biomarker Working Group guidelines . Results : Tumours were classified into high and low TIL groups using the interquartile range cutoff (29%). High CD4 group showed increased pCR (p = 0.003) and smaller residual tumours (p = 0.04). High CD8 group showed a significant association with smaller residual tumours (p = 0.003). At follow-up of 24-months, CD4 and CD8 high groups showed significantly higher 2-years DFS. The difference between CD4 high and low groups was significant in regards to estrogen receptor status, showing higher levels in hormone-negative tumors ( p = 0.029). Patients with Her2 subtype showed higher CD4 ( p = 0.007) and CD8 expression ( p = 0.018). In CD4 & CD8 low groups, more patients developed local recurrence and distant metastasis ( p = 0.025). Conclusion : We concluded that TILs may predict response to NAC and overall prognosis of breast cancer. The evaluation of TILs in correlation with morphological or genomics-based parameters helps to stratify patients of breast cancer.
Mamounas, E.P. (2015) Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer. Annals of Surgical Oncology, 22, 1425-1433. https://doi.org/10.1245/s10434-015-4406-6
Sasanpour, P., Sandoughdaran, S., Mosavi-Jarrahi, A. and Malekzadeh, M. (2018) Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 19, 2423-2427.
Pruneri, G., Vingiani, A. and Denkert, C. (2017) Tumor Infiltrating Lymphocytes in Early Breast Cancer. Breast, 37, 207-214. https://doi.org/10.1016/j.breast.2017.03.010
Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Hatano, T., et al. (2018) Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-Infiltrating Lymphocytes. Anticancer Research, 38, 2311-2321. https://doi.org/10.21873/anticanres.12476
Dushyanthen, S., Beavis, P.A., Savas, P., Teo, Z.L., Zhou, C., Mansour, M., et al. (2015) Relevance of Tumor-Infiltrating Lymphocytes in Breast Cancer. BMC Medicine, 13, 202. https://doi.org/10.1186/s12916-015-0431-3
Heppner, B., Loibl, S. and Denkert, C. (2016) Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care, 11, 96-100. https://doi.org/10.1159/000444357
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B.M., Komor, M., et al. (2010) Tumor-Associated Lymphocytes as an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 105-113. https://doi.org/10.1038/nrc3239
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. (2007) Toll-Like Receptor 4-Dependent Contribution of the Immune System to Anticancer Chemotherapy and Radiotherapy. Nature Medicine, 13, 1050-1059. https://doi.org/10.1038/nm1622
Mattarollo, S.R., Loi, S., Duret, H., Ma, Y., Zitvogel, L. and Smyth, M.J. (2011) Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Research, 71, 4809-4820. https://doi.org/10.1158/0008-5472.CAN-11-0753
Andre, F., Dieci, M.V., Dubsky, P., Sotiriou, C., Curigliano, G., Denkert, C., et al. (2013) Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. Clinical Cancer Research, 19, 28-33. https://doi.org/10.1158/1078-0432.CCR-11-2701
Cimino-Mathews, A., Foote, J.B. and Emens, L.A. (2015) Immune Targeting in Breast Cancer. Oncology, 29, 375-385.
Bianchini, G., Qi, Y., Alvarez, R.H., Iwamoto, T., Coutant, C., Ibrahim, N.K., et al. (2010) Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers. Journal of Clinical Oncology, 28, 4316-4323. https://doi.org/10.1200/JCO.2009.27.2419
Sahoo, S. and Leste, S.C. (2019) Pathology of Breast Carcinomas after Neoadjuvant Chemotherapy. An Overview with Recommendations on Specimen Processing and Reporting. Archives of Pathology & Laboratory Medicine, 133, 633-642.
Hendry, S., Salgado, R., Gevaert, T., Russell, P.A., John, T., Thapa, B., et al. (2017) Assessing Tumor Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 24, 235-251.
Pelekanou, V., Carvajal-Hausdorf, D.E., Altan, M., Wasserman, B., Carvajal-Hausdorf, C., Wimberly, H., et al. (2017) Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance. Breast Cancer Research, 19, 1-11. https://doi.org/10.1186/s13058-017-0898-2
Mao, Y., Qu, Q., Zhang, Y., Liu, J., Chen, X. and Shen, K. (2014) The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 9, e115103. https://doi.org/10.1371/journal.pone.0115103
Kashiwagi, S., Asano, Y., Goto, W., Takada, K., Takahashi, K., Hatano, T., et al. (2017) Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-Positive Breast Cancer. Anticancer Research, 37, 5623-5630. https://doi.org/10.21873/anticanres.11997
Zitvogel, L., Kepp, O. and Kroemer, G. (2011) Immune Parameters Affecting the Efficacy of Chemotherapeutic Regimens. Nature Reviews Clinical Oncology, 8, 151-160. https://doi.org/10.1038/nrclinonc.2010.223
Dougan, M. and Dranoff, G. (2009) Immune Therapy for Cancer. Annual Review of Immunology, 27, 83-117. https://doi.org/10.1146/annurev.immunol.021908.132544
Criscitiello, C., Esposito, A., Trapani, D. and Curigliano, G. (2016) Prognostic and Predictive Value of Tumor Infiltrating Lymphocytes in Early Breast Cancer. Cancer Treatment Reviews, 50, 205-207. https://doi.org/10.1016/j.ctrv.2016.09.019
Tang, H., Qiao, J. and Fu, Y.X. (2016) Immunotherapy and Tumor Microenvironment. Cancer Letters, 370, 85-90. https://doi.org/10.1016/j.canlet.2015.10.009
Taube, J.M., Galon, J., Sholl, L.M., Rodig, S.J., Cottrell, T.R., Giraldo, N.A., et al. (2018) Implications of the Tumor Immune Microenvironment for Staging and Therapeutics. Modern Pathology, 31, 214-234. https://doi.org/10.1038/modpathol.2017.156
Kotoula, V., Chatzopoulos, K., Lakis, S., Alexopoulou, Z., Timotheadou, E., Zagouri, F., et al. (2016) Tumors with High-Density Tumor Infiltrating Lymphocytes Constitute a Favorable Entity in Breast Cancer: A Pooled Analysis of Four Prospective Adjuvant Trials. Oncotarget, 7, 5074-5087. https://doi.org/10.18632/oncotarget.6231
Jang N, Kwon HJ, Park MH, Kang SH and Bae YK (2018) Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. Annals of Surgical Oncology, 25, 937-946. https://doi.org/10.1245/s10434-017-6332-2
Herrero-Vicent, C., Guerrero, A., Gavilá, J., Gozalbo, F., Hernández, A., Sandiego, S., et al. (2017) Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. Cancer, 11, 759. https://doi.org/10.3332/ecancer.2017.759
Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., et al. (2015) Tumor-Infiltrating Lymphocytes and Associations with Pathological Complete Response and Event-Free Survival in HER2-Positive Early Stage Breast Cancer Treated with Lapatinib and Trastuzumab. JAMA Oncology, 1, 448-454. https://doi.org/10.1001/jamaoncol.2015.0830
Denkert, C., von Minckwitz, G., Brase, J.C., Sinn, B.V., Gade, S., Kronenwett, R., et al. (2015) Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy with or without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. Journal of Clinical Oncology, 33, 983-991. https://doi.org/10.1200/JCO.2014.58.1967
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., et al. (2013) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31, 860-867. https://doi.org/10.1200/JCO.2011.41.0902
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., et al. (2014) Tumor-Infiltrating Lymphocytes Are Prognostic in Triple Negative Breast Cancer and Predictive for Trastuzumab Benefit in Early Breast Cancer: Results from the FinHER Trial. Annals of Oncology, 25, 1544-1550. https://doi.org/10.1093/annonc/mdu112
Issa-Nummer, Y., Darb-Esfahani, S., Loibl, S., Nekljudova, V., Schrader, I., Sinn, B.V., et al. (2013) Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer: A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS ONE, 8, e79775. https://doi.org/10.1371/journal.pone.0079775